Thomas E. Sepe, MD

Thomas E. Sepe, MD

Clinical Professor of Medicine


Email: [email protected]

Academic Interests

My research involves overseeing a robust clinical trials unit in liver disease that has conducted over 70 Research Trials in Hepatitis C infection. My interests encompass  liver disease and specifically the care and therapy of Hepatitis C infection. We also  now focus on disease specific drug therapy of NASH(non-alcoholic steatohepatitis) and cirrhosis.

Select Publications

Liver enzymes: No trivial elevations, even if asymptomatic. Agganis B, Lee D, Sepe T. Cleve Clin J Med. 2018 Aug;85(8):612-617. doi: 10.3949/ccjm.85a.17103. Review. Erratum in: Cleve Clin J Med. 2018 Oct;85(10):737. PMID: 30102591

Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1. Bourlière M, Gordon SC, Schiff ER, Tran TT, Ravendhran N, Landis CS, Hyland RH, Stamm LM, Zhang J, Dvory-Sobol H, Subramanian GM, Brainard DM, McHutchison JG, Serfaty L, Thompson AJ, Sepe TE, Curry MP, Reddy KR, Manns MP. Lancet Gastroenterol Hepatol. 2018 Aug;3(8):559-565. doi: 10.1016/S2468-1253(18)30118-3. Epub 2018 May 31. PMID:   29859740

Pancreatic lymphoma complicating early stage chronic hepatitis C. Bhagat VH, Sepe T. BMJ Case Rep. 2017 Jan 10;2017. pii: bcr2016216698. doi: 10.1136/bcr-2016-216698. PMID:  28073869

Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. Poordad F, Sievert W, Mollison L, Bennett M, Tse E, Bräu N, Levin J, Sepe T, Lee SS, Angus P, Conway B, Pol S, Boyer N, Bronowicki JP, Jacobson I, Muir AJ, Reddy KR, Tam E, Ortiz-Lasanta G, de Lédinghen V, Sulkowski M, Boparai N, McPhee F, Hughes E, Swenson ES, Yin PD; UNITY-1 Study Group. JAMA. 2015 May 5;313(17):1728-35. doi: 10.1001/jama.2015.3860. PMID: 25942723